SCHEMBL20133234

SCHEMBL20133234

c1ccc(CO[C@H]2C[C@H](OCCCOCCOC3CCCCO3)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4C Q9H3R0 1/20 0.41
FOXM1 Q08050 1/20 0.35
BCHE P06276 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
EP300 Q09472 1/20 0.34
CREBBP Q92793 1/20 0.34
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSK P43235 1/20 0.33
TACR1 P25103 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
DPP4 P27487 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
SSTR1 P30872 1/20 0.33
SSTR2 P30874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20120793 0.98 MEN1 (0.46) MEN1KMT2AKDM4CFOXM1BCHE
SCHEMBL20120795 0.98 MEN1 (0.46) MEN1KMT2AKDM4CFOXM1BCHE
SCHEMBL20133212 0.95 MEN1 (0.48) MEN1KMT2AKDM4CFOXM1BCHE
SCHEMBL21771133 0.95 MEN1 (0.47) MEN1KMT2AKDM4CBCHEL3MBTL1
SCHEMBL21751819 0.95 MEN1 (0.47) MEN1KMT2AKDM4CBCHEL3MBTL1
SCHEMBL20128955 0.93 MEN1 (0.50) MEN1KMT2AKDM4CBCHEL3MBTL1
SCHEMBL20128933 0.93 MEN1 (0.50) MEN1KMT2AKDM4CBCHEL3MBTL1
SCHEMBL20133087 0.93 MEN1 (0.50) MEN1KMT2AKDM4CBCHEL3MBTL1
SCHEMBL24765047 0.93 KDM4C (0.45) MEN1KMT2AKDM4CBCHEL3MBTL1
SCHEMBL20233781 0.93 KDM4C (0.45) MEN1KMT2AKDM4CBCHEL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN MEN1 1944/4885KMT2A 1250/4885KDM4C 2111/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885KDM4C 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.